Lonsurf

Chemical Nametrifluridine and tipiracil
Dosage FormTablet (oral; trifluridine mg/ tipiracil mg: 15 mg/6.14 mg, 20 mg/8.19 mg)
Drug ClassInhibitors
SystemDigestive
CompanyTaiho Oncology
Approval Year2015

Indication

  • For treatment of metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
  • For treatment of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lonsurf (trifluridine and tipiracil) Prescribing Information2019Taiho Oncology, Inc., Princeton, NJ